Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Cancer Research|December 21, 2006
Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancerJoanne N Davis, Kirk J Wojno, Stephanie Daignault, et al.
Oncogene|September 4, 2025
TRIM29 promotes bladder cancer invasion by regulating the intermediate filament network and focal adhesionYin Wang, Nicole A Jerome, Alan J Kelleher, et al.
Oncoimmunology|September 14, 2016
Targeting CD73 in the tumor microenvironment with MEDI9447Carl M Hay, Erin Sult, Qihui Huang, et al.
Frontiers in Oncology|January 11, 2021
A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted ActivityJonathan Rios-Doria, Margaret Favata, Kerri Lasky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2003
The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancerRainer Kuefer, Matthias D Hofer, Juergen E Gschwend, et al.
Molecular Cancer Therapeutics|May 8, 2015
A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated PathwaysJonathan Rios-Doria, Darrin Sabol, Jon Chesebrough, et al.
Oncotarget|November 20, 2020
MEK is a promising target in the basal subtype of bladder cancerNathan M Merrill, Nathalie M Vandecan, Kathleen C Day, et al.
Molecular Medicine (Cambridge, Mass.)|October 30, 2013
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancerPetros D Grivas, Kathleen C Day, Andreas Karatsinides, et al.
Plos One|October 4, 2011
Repression of androgen receptor transcription through the E2F1/DNMT1 axisConrad David Valdez, Joanne N Davis, Hana M Odeh, et al.
Neoplasia (New York, N.Y.)|June 8, 2006
ADAM15 disintegrin is associated with aggressive prostate and breast cancer diseaseRainer Kuefer, Kathleen C Day, Celina G Kleer, et al.
Pageof 6